CYTK
Price
$32.30
Change
+$0.22 (+0.69%)
Updated
Jun 6 closing price
Capitalization
3.86B
53 days until earnings call
IMVT
Price
$16.77
Change
+$0.75 (+4.68%)
Updated
Jun 6 closing price
Capitalization
2.87B
59 days until earnings call
Interact to see
Advertisement

CYTK vs IMVT

Header iconCYTK vs IMVT Comparison
Open Charts CYTK vs IMVTBanner chart's image
Cytokinetics
Price$32.30
Change+$0.22 (+0.69%)
Volume$768.26K
Capitalization3.86B
Immunovant
Price$16.77
Change+$0.75 (+4.68%)
Volume$2.18M
Capitalization2.87B
CYTK vs IMVT Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. IMVT commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and IMVT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (CYTK: $32.30 vs. IMVT: $16.77)
Brand notoriety: CYTK and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 35% vs. IMVT: 152%
Market capitalization -- CYTK: $3.86B vs. IMVT: $2.87B
CYTK [@Biotechnology] is valued at $3.86B. IMVT’s [@Biotechnology] market capitalization is $2.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, IMVT is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while IMVT’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 2 bearish.
  • IMVT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than IMVT.

Price Growth

CYTK (@Biotechnology) experienced а +4.13% price change this week, while IMVT (@Biotechnology) price change was +12.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

IMVT is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($3.86B) has a higher market cap than IMVT($2.87B). CYTK (-31.335) and IMVT (-32.297) have similar YTD gains . IMVT has higher annual earnings (EBITDA): -404.87M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. IMVT (375M). IMVT has less debt than CYTK: IMVT (23K) vs CYTK (791M). CYTK has higher revenues than IMVT: CYTK (19.2M) vs IMVT (0).
CYTKIMVTCYTK / IMVT
Capitalization3.86B2.87B135%
EBITDA-513.62M-404.87M127%
Gain YTD-31.335-32.29797%
P/E RatioN/AN/A-
Revenue19.2M0-
Total Cash938M375M250%
Total Debt791M23K3,439,130%
FUNDAMENTALS RATINGS
CYTK vs IMVT: Fundamental Ratings
CYTK
IMVT
OUTLOOK RATING
1..100
633
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
8662
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5040

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (46) in the null industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as IMVT (100) in the null industry. This means that CYTK’s stock grew similarly to IMVT’s over the last 12 months.

IMVT's SMR Rating (94) in the null industry is in the same range as CYTK (99) in the Biotechnology industry. This means that IMVT’s stock grew similarly to CYTK’s over the last 12 months.

IMVT's Price Growth Rating (62) in the null industry is in the same range as CYTK (86) in the Biotechnology industry. This means that IMVT’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that CYTK’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKIMVT
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 12 days ago
78%
Bearish Trend 12 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VMSGX21.620.25
+1.17%
VALIC Company I Mid Cap Strategic Gr
VFFSX294.243.03
+1.04%
Vanguard 500 Index Institutional Select
JFNIX66.370.63
+0.96%
Janus Henderson Global Life Sciences I
WBCIX15.950.15
+0.95%
William Blair Small-Mid Cap Core I
ZGFIX19.800.13
+0.66%
American Beacon Ninety One Gbl Frnchs R5

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with KRYS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+0.69%
KRYS - CYTK
47%
Loosely correlated
+3.26%
IDYA - CYTK
47%
Loosely correlated
+2.99%
IMVT - CYTK
46%
Loosely correlated
+4.68%
TRDA - CYTK
44%
Loosely correlated
+2.46%
ACLX - CYTK
44%
Loosely correlated
+2.79%
More

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+4.68%
ROIV - IMVT
60%
Loosely correlated
+0.27%
OCUL - IMVT
49%
Loosely correlated
+6.62%
COGT - IMVT
49%
Loosely correlated
+13.52%
KYMR - IMVT
48%
Loosely correlated
-0.08%
XENE - IMVT
48%
Loosely correlated
+2.96%
More